✓ Medically reviewed✍️ HairBase editorial team📅 Last updated: September 7, 2026⏱ 1 min read
💡 Quick answer
Dutasteride 0.5 mg blocks both 5AR isoforms, suppressing more DHT than finasteride. It is approved for hair loss in Korea & Japan and off-label in the
As an AliExpress affiliate, we may earn a commission from qualifying purchases.
Evidence B · Promising
How it is sold where you are
Korea & Japan: dutasteride 0.5 mg has a hair-loss indication. US/EU: typically licensed for BPH and used off-label for hair — confirm locally; this is not a prescription.
Dutasteride 0.5 mg blocks both 5AR isoforms, suppressing more DHT than finasteride. It is approved for hair loss in Korea & Japan and off-label in the US/EU. The same pregnancy precautions apply.
Dutasteride is one piece — build the whole plan
See how it ranks against every option, tuned to your stage, goal and budget.
2002FDA approves oral dutasteride (Avodart, 0.5 mg) — a dual type I/II 5-alpha-reductase inhibitor — for benign prostatic hyperplasia, establishing the molecule and safety profile later repurposed off-label for hair loss.
2006Olsen et al. publish the first major randomized placebo-controlled dose-ranging trial of dutasteride vs finasteride for male pattern hair loss in JAAD, demonstrating dose-dependent hair regrowth and superiority of higher-dose dutasteride to finasteride.
2009South Korea becomes the first country to approve oral dutasteride 0.5 mg/day specifically for male androgenetic alopecia (the indication remains off-label in the US/EU).
2015Japan's PMDA approves dutasteride 0.5 mg (Zagallo) for male androgenetic alopecia, the second national regulatory approval for this indication (Deliberation Results, Sept 2015).
2014Gubelin Harcha et al. publish the large pivotal phase IIb/III RCT (917 men) in JAAD confirming dutasteride 0.5 mg significantly outperforms finasteride 1 mg on 24-week hair count, supporting the approvals.
Dutasteride increased target-area hair count vs placebo in a dose-dependent manner; dutasteride 2.5 mg/day was superior to finasteride 5 mg/day at weeks 12 and 24, establishing that dual 5-alpha-reductase inhibition (lowering both scalp and serum DHT more completely) yields greater regrowth.
J Am Acad Dermatol (JAAD)
Gubelin Harcha et al., 20142014
Randomized, active- and placebo-controlled phase IIb/III RCT; 917 men aged 20-50, 24 weeks
Men received dutasteride 0.02/0.1/0.5 mg, finasteride 1 mg, or placebo daily. Hair count increased with dutasteride dose-dependently; dutasteride 0.5 mg significantly improved hair count, hair width and hair-growth assessment vs finasteride 1 mg at week 24 (reported P values ~.002-.004). This is the largest head-to-head trial and the basis for the Asian approvals.
153 Korean men aged 18-49, randomized to oral dutasteride 0.5 mg/day vs placebo for 6 months (phase III, double-blind, placebo-controlled)
Oral dutasteride 0.5 mg/day significantly increased hair counts vs placebo over 6 months (+12.2/cm2 vs +4.7/cm2, P=.0319), with improved subject and investigator/panel photographic assessments. Note: this was an oral trial (not mesotherapy) and was placebo-controlled (no in-trial finasteride comparator).
J Am Acad Dermatol (JAAD)
Herz-Ruelas et al., 20202020
Systematic review of 8 studies (5 oral, 3 intralesional/mesotherapy dutasteride)
Both oral and intralesional (mesotherapy) dutasteride improved hair count, but evidence for the injectable route was weak: mean hair-count increase was larger for oral (MD ~15.9 hairs) than intralesional (MD ~7.9 hairs in a single study). Authors concluded data were insufficient for reliable route comparison — intralesional dutasteride remains experimental with low-quality, heterogeneous evidence.
Skin Appendage Disord (PMID 33313048)
Latest research: Recent work (2023-2026) focuses on alternative routes and dosing to keep dutasteride's potency while limiting systemic DHT suppression — including intralesional/mesotherapy dutasteride (a 2025 Journal of Cosmetic Dermatology systematic review/meta-analysis showed promising local hair-count gains but flagged small samples and high heterogeneity), low-dose 0.2 mg phase III trials, and intermittent (twice/thrice-weekly) oral regimens versus daily finasteride. A 2025 Bayesian network meta-analysis of ~33 RCTs also ranked oral dutasteride 0.5 mg/day as the most effective monotherapy for male AGA by 24-week hair density (highest SUCRA).
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Dutasteride blocks both 5AR isoenzymes and lowers DHT more strongly, but stronger suppression does not automatically mean better results or fewer side effects for everyone. In Korea both are available for hair loss, so the right choice depends on your side-effect history and goals and is best made with a clinician.
Which countries approve dutasteride for hair loss?
It is formally approved for androgenetic alopecia in South Korea and Japan. In the US and EU it is approved only for benign prostate enlargement and is prescribed off-label for hair loss, so how it's prescribed may differ depending on where you live.
What should I know about its long half-life?
Dutasteride stays in the body longer than finasteride, so some effect persists for a while even after you stop. This is why blood donation is usually avoided for a period after discontinuing, and why it's especially important that anyone who could become pregnant is not exposed to the drug. Discuss this fully with a clinician before starting.
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Figures such as 1 mg or 5% are labelled strengths you may see in your country — not a dosing instruction. Consult a board-certified dermatologist before starting, stopping or changing any treatment.